Protagonist Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Protagonist Therapeutics

05/05/2025 22:08

Protagonist Therapeutics Inc PTGX.OQ PTGX.O is expected to show a fall in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

The Newark California California-based  company is expected to report a 88.1% decrease in revenue to $30.444 million from $254.95 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Protagonist Therapeutics Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 12.2% in the last three months. ​

Wall Street's median 12-month price target for Protagonist Therapeutics Inc is $70.00​, above​ its last closing price of $45.51. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
0.63
0.32
1.98
Beat
516.6
Sep. 30 2024
-0.58
-0.61
-0.54
Beat
11.1
Jun. 30 2024
-0.57
-0.60
-0.50
Beat
16.9​
Mar. 31 2024
0.54
1.19
3.26
Beat
173.1
​​Dec. 31 2023
0.03
-0.03
0.44
Beat
1,425.3
Sep. 30 2023
-0.70
-0.69
-0.58
Beat
16.4​
Jun. 30 2023
-0.65
-0.65
-0.68
Missed
-5
Mar. 31 2023
-0.77
-0.73
-0.67
Beat
7.8

This summary was machine generated May 5 at 21:08 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)